World's first Total-Body PET scanner could revolutionize cancer detection

NCT ID NCT05160480

ENROLLING_BY_INVITATION Diagnosis Sponsor: University of California, Davis Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study is testing the world's first total-body PET/CT scanner (EXPLORER) to see if it can improve cancer imaging. Researchers will scan 9 people with prostate cancer, breast cancer, or neuroendocrine tumors using FDA-approved radiotracers. The goal is to measure how well these tracers highlight tumors over time, potentially leading to more accurate detection and monitoring.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Total-body PET imaging with radiotracers (18F-PSMA, 18F-FES, 68Ga DOTATATE)
What this could lead to: If successful, this could lead to more detailed and accurate cancer imaging, helping doctors better detect and monitor tumors.
What could go wrong: This is a very small pilot study with only 9 participants, so results may not apply broadly. It is testing imaging methods, not a treatment, so direct patient benefits are uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm neuroendocrine neoplasm prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER NEUROENDOCRINE TUMORS PROSTATE CANCER

Contacts and locations

Locations

UC Davis EXPLORER Molecular Imaging Center

Sacramento, California, 95816, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.